Program
Estradiol
Also written as “NOMAC-E2”, “estradiol, 25 mcg” and “estradiol, 10 mcg”.
Its studies are mostly in Hot Flashes · Dyspareunia · Atrophic Vaginitis · Leiomyoma · Menorrhagia, led by 21 companies.
Drug pageEstradiol: every studyMany companies study it; this page follows only the 55 they lead. All 300 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordiskits history only | 120 open or running | phase 4since Oct 8, 2012 | Apr 19, 2005 | none ahead |
| Bayerits history only | 100 open or running | phase 4since Sep 12, 2005 | Sep 9, 2005 | none ahead |
| AbbVieits history only | 80 open or running | phase 3since Feb 17, 2010 | Feb 17, 2010 | none ahead |
| Teva Pharmaceutical Industriesits history only | 30 open or running | phase 3since Nov 7, 2022 | Jul 2, 2010 | none ahead |
| TherapeuticsMDits history only | 30 open or running | phase 3since Sep 5, 2013 | Sep 5, 2013 | none ahead |
| Grünenthalits history only | 20 open or running | phase 1since Nov 9, 2018 | Nov 9, 2018 | none ahead |
| Merckits history only | 20 open or running | phase 1since Nov 26, 2008 | Nov 26, 2008 | none ahead |
| Renovoits history only | 20 open or running | phase 3since Jan 24, 2007 | Jan 24, 2007 | none ahead |
| Amneal Pharmaceuticalsits history only | 10 open or running | phase 3since Jan 28, 2013 | Jan 28, 2013 | none ahead |
| ASCEND Therapeuticsits history only | 10 open or running | phase 4since Sep 8, 2005 | Sep 8, 2005 | none ahead |
| BioSante Pharmaceuticalsits history only | 10 open or running | phase 3since Oct 20, 2006 | Oct 20, 2006 | none ahead |
| Centro A.F. de Estudios Tecnologicosits history only | 10 open or running | phase 3since Oct 16, 2008 | Oct 16, 2008 | none ahead |
| Corium Innovationsits history only | 11 open or running | phase 1since Aug 26, 2026 | Aug 26, 2026 | May 31, 2027phase 1 · NCT07794150 |
| Hamad Medicalits history only | 10 open or running | phase 2since Apr 6, 2021 | Apr 6, 2021 | none ahead |
| Lotus Pharmaceuticalits history only | 10 open or running | phase 3since Dec 14, 2016 | Dec 14, 2016 | none ahead |
| Padagisits history only | 10 open or running | phase 3since May 10, 2016 | May 10, 2016 | none ahead |
| Prascoits history only | 10 open or running | phase 3since Nov 1, 2017 | Nov 1, 2017 | none ahead |
| Productos Científicos S. A. de C. V.its history only | 10 open or running | phase 1since Feb 10, 2011 | Feb 10, 2011 | none ahead |
| Sun Pharmaceutical Industriesits history only | 10 open or running | phase 3since Dec 15, 2012 | Dec 15, 2012 | none ahead |
| Upsher-Smith Laboratoriesits history only | 10 open or running | phase 3since Jul 29, 2008 | Jul 29, 2008 | none ahead |
| Viramal | 10 open or running | phase 1since Jun 1, 2018 | Jun 1, 2018 | none ahead |
Also a collaborator on its studies: IQVIA Pty, Abbott, Simbec Research, Laboratoires Besins International and Grünenthal.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Viramal only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 1, 2018First study: phase 1 study in MenopauseFirst studyNCT03556800 · 20 enrolled · United Kingdom
TargetBeta
“Estrogen receptor alpha agonist”ChEMBL 37, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
The one study Viramal leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03556800Menopause · United Kingdom | 1 | UNKNOWN | Jun 30, 2022 | 20 |
How it is read
Names in the registry
- “Estradiol”, 7 entries
- “NOMAC-E2”, 6 entries
- “estradiol, 25 mcg”, 5 entries
- “estradiol, 10 mcg”, 4 entries
- “Zesteem”, 4 entries
Conditions, from the studies’ own filings
- Hot Flashes, 9 studies
- Dyspareunia, 4 studies
- Atrophic Vaginitis, 2 studies
- Leiomyoma, 2 studies
- Menorrhagia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.